Dynamics of hormonal parameters in patients with climacteric syndrome in the context of hypothyroidism under the influence of complex therapy with Climact-Hel and Mulimen
In hypothyroidism, the climacteric syndrome has a tendency to an early start and a protracted course and manifests itself in the middle and severe forms with a predominance in the clinical picture of psychoemotional and metabolic-endocrine disorders. The purpose of the work is to compare the effectiveness of complex treatment of climacteric syndrome with concomitant hypothyroidism by analyzing hormonal indices before and after complex therapy using antihomotoxicological therapy. For its achievement, patients are divided into two groups: women who received only baseline therapy in accordance with the National Consensus on the management of patients in the climacteric diet (hereinafter — base therapy, group 1) and patients who, in addition to the baseline therapy, received therapy with antihomotoxic drugs (Group 2). After analyzing the patient's outcomes with the climacteric syndrome and concomitant hypothyroidism after the two treatment courses, there was a tendency for the IRI to decrease in both groups, but none of the groups was able to reach the normal level. Calcitriol increased in two observation groups, while in one group the index did not reach normal values. The decrease in the follicle stimulating hormone was observed in both groups and only the 1st group managed to get closer to normal values after two treatment cycles. The decrease in estradiol was observed in both groups of patients, but its significance was significantly lower in patients in the 1st group. Under the influence of treatment in accordance with the protocols in the first group, TTG significantly decreased, reaching the norm after the second course of treatment. In assessing the overall effectiveness of treatment, it turned out that with the use of baseline therapy, the effectiveness was 63.3%, with the use of complex treatment with the use of antihomotoxic drugs — 55.5%.
2. Deryabina, E. G. & Bashmakova, N. V. (2012). Shitovidnaya zheleza i menopauza. [Thyroid gland and menopause]. Ekaterinburg.
3. Korolevskaya, L. I., Turova, E. A. & Tenyaeva, E. A. (2009). Programmy vosstanovitelnoj mediciny v korrekcii proyavlenij klimaktericheskogo sindroma i profilaktiki osteoporoza. [Programs of restorative medicine in correction of manifestations of menopausal syndrome and prevention of osteoporosis]. Vestnik vosstanovitelnoj mediciny – Bulletin of Restorative Medicine, 2, 88–90.
4. Manuhin, I. B., Tumilovich, L. G., Gevorkyan, M. A. & Manuhina, E. I. (2017). Ginekologicheskaya endokrinologiya: klinicheskie lekcii. [Gynecological endocrinology: clinical lectures]. (4-e izd., pererab. i dop.). Moskva: GEOTAR-Media.
5. Serov, V. N., Prilepskaya, V. N. & Ovsyannikova, T. V. (2017). Ginekologicheskaya endokrinologiya. [Gynecological endocrinology]. (6-e izd.). Moskva: MEDpress-inform.
6. Smetnik, V. P. (Red.). (2006). Medicina, klimakteriya. [Medicine, menopause]. Moskva: Litera.
7. Hashaeva, T. H. & Esedova, E. (2001). Primenenie preparata Klimen v lechenii klimaktericheskih rasstrojstv u zhenshin s endemicheskim zobom. [The use of the drug Klimen in the treatment of climacteric disorders in women with endemic goiter]. Ginekologiya – Gynecology, 3 (1), 14–7.
8. Acar, B., Ozay, A. C., Ozay, O. E., Okyay, E., Sisman, A. R. & Ozaksoy, D. (2016). Evaluation of thyroid function status among postmenopausal women with and without osteoporosis. Int. J. Gynaecol. Obstet., 134 (1), 53–7. doi: 10.1016/j.ijgo.2015.11.025.
9. Badawy, A., State, O. & Sherief, S. (2007). Can thyroid dysfunction explicate severe menopausal symptoms? J. Obstet. Gynaecol., 27 (5), 503–5.
10. Ceresini, G., Milli, B., Morganti, S., Maggio, M., Bacchi-Modena, A., Sgarabotto, M. P. … Valenti, G. Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women. Menopause. 2008 Mar-Apr;15(2):326–31. DOI:10.1097/gme.0b013e318148b83e.
11. Del Ghianda, S., Tonacchera, M. & Vitti, P. (2014). Thyroid and menopause. Climacteric., 17 (3), 225–34. doi: 10.3109/13697137.2013.838554.
12. Gietka-Czernel, M. (2017). The thyroid gland in postmenopausal women: physiology and diseases. Prz Menopauzalny., 16 (2), 33–37. doi: 10.5114/pm.2017.68588.
13. Hernández Valencia, M., Córdova Pérez, N., Zárate, A., Basurto, L., Manuel Apolinar, L., Ruiz, M. … Vargas, A. (2008). Hypothyroidism associated to menopause symptoms worsening change with thyroid substitution therapy. Ginecol. Obstet. Mex., 76 (10), 571–5. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19062505.
14. Lambrinoudaki, I., Armeni, E., Rizos, D., Georgiopoulos, G., Kazani, M., Alexandrou, A. … Stamatelopoulos, K. (2012). High normal thyroid-stimulating hormone is associated with arterial stiffness in healthy postmenopausal women. J. Hypertens., 30 (3), 592–9. doi: 10.1097/HJH.0b013e32834f5076.
15. Pearce, E. N. (2007). Thyroid dysfunction in perimenopausal and postmenopausal women. Menopause Int. 13 (1), 8–13. DOI: 10.1258/175404507780456746.
This work is licensed under a Creative Commons Attribution 4.0 International License.